A Phase 3 interventional study of Pregabalin and Placebo matched with pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 10 in phase 3, and was the 15th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 626 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 241 across the 17 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
12 studies in Diabetic Neuropathies by Viatris Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 5 (42%) have results posted.
Among the 12 studies in Diabetic Neuropathies by Viatris Inc., this one is the 2nd largest by enrollment, is the only one that started in 2011, is one of 8 in phase 3, and was the 12th registered.
Viatris Inc.’s Diabetic Neuropathies studies by the year they started, since 1998.
1 of the studies testing pregabalin in Diabetic Neuropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 12 in Diabetic Neuropathies:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.
This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient take pregabalin capsule twice a day
Drug: Pregabalin
Drug: Placebo matched with pregabalin
Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn. At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.
Subject will take placebo matched with pregabalin twice a day.
Baseline Mean Pain Score
The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
Time frame: Baseline
Change From Baseline in Mean Pain Score at Endpoint
The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint pain score was obtained from the last 7 available DPRS scores of the daily pain diary while the participant was on study medication, up to and including the day after the last Week 8 (Day 57) dose.
Time frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Change From Baseline in Weekly Mean Pain Score at Weeks 1 to 9
The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean pain score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.
Time frame: Baseline and weekly from Weeks 1 to 9
Baseline Mean Sleep Interference Score
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10.
Time frame: Baseline
Change From Baseline in Mean Sleep Interference Score at Endpoint
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint score was obtained from the last 7 available scores of the daily diary while the participant was on study medication, up to and including the day after the last Week 9 (Day 63) dose.
Time frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Change From Baseline in Weekly Mean Sleep Interference Score at Weeks 1 to 9
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.
Time frame: Baseline and weekly from Weeks 1 to 9
Percentage of 30 Percent (%) Responders at Endpoint
The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. A 30% responder was a participant who had 30% reduction or more in mean pain score at the end of the fixed dose phase (Day 63/Week 9) (Study Endpoint) compared to baseline.
Time frame: End of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Change From Baseline in Short Form McGill Pain Questionnaire (SF-MPQ) Score at Weeks 1, 5, and 9
SF-MPQ was assessed according to the participant's answer to the SF-MPQ questionnaire. The score for each composite scale (sensory, affective, and total) was derived by summing the reported intensity value for each item within a particular scale where None=0, Mild=1, Moderate=2, and Severe=3. The sensory score was the sum of the scores of the first 11 pain descriptors (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, and splitting) and could range from 0-33. The affective score was the sum of the scores of the last 4 pain descriptors (tiring-exhausting, sickening, fearful, and punishing-cruel) and could range from 0-12. The total score was the sum of the scores of all 15 pain descriptors and could range from 0 to 45. Higher scores indicated greater pain.
Time frame: Baseline; Weeks 1, 5, and 9
Baseline Pain Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) Scale
The VAS was part of the Short Form McGill Pain Questionnaire (SF-MPQ) scale and reflected the overall pain intensity score, The pain VAS was a horizontal line; 100 millimeters (mm) in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain). The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).
Time frame: Baseline
Change From Baseline in Pain VAS From the SF-MPQ at Endpoint
The VAS was part of the SF-MPQ scale and reflected the overall pain intensity score. The pain VAS was a horizontal line; 100 mm in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain).
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in PPI Scale From the SF-MPQ at Endpoint
The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Baseline Medical Outcomes Study (MOS)-Sleep Scale Scores
The MOS-Sleep Scale was a participant-rated instrument which assesses sleep quantity and quality with 12 items (7 subscale scores: sleep disturbance, snoring, awakening short of breath/with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep; and a 9-item overall sleep problems index). Subscale scores total range: 0-100 (except sleep quantity \[range 0-24 hours\], optimal sleep \[yes:1, no:0\]). Higher scores=poorer sleep outcomes (except sleep quantity, adequacy, and optimal sleep).
Time frame: Baseline
Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. For sleep disturbance, the subscale score also ranged from 0 to 100, with higher scores representing greater sleep disturbance.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The snoring subscale score also ranged from 0 to 100, with lower scores indicating less snoring.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The awaken short of breath subscale also ranged from 0 to 100, with lower scores indicating less difficulty in breathing.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS Sleep Quantity sub-scale scores ranged from 0 to 24 (number of hours slept).
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Percentage of Participants Who Had Optimal Sleep at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS optimal sleep subscale was a binary outcome derived from the sleep quantity responses: the response was YES if sleep quantity was 7 or 8 hours per night.
Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep adequacy subscale also ranged from 0 to 100, with higher scores indicating greater sleep adequacy.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The somnolence subscale score also ranged from 0 to 100, with lower scores indicating less somnolence.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep problems index subscale score also ranged from 0 to 100, with lower scores indicating fewer sleep problems.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Clinical Global Impression of Change (CGIC) at Endpoint
The CGIC was a clinician-rated global measure that provided a clinically relevant and easy to interpret account of a clinician's perception of the clinical importance of the participant's improvement or worsening during their involvement in a clinical study. Clinicians rated the participant's overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).
Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)
Patient Global Impression of Change (PGIC) Score at Endpoint
The PGIC was a participant-rated global measure that provided a clinically relevant and easy to interpret account of a participant's perception of the clinical importance of their own improvement or worsening during their involvement in a clinical study. Participants rated their overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).
Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)
Baseline Hospital Anxiety and Depression Scale (HADS) Scores
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
Time frame: Baseline
Change From Baseline in HADS Anxiety Total Score at Endpoint
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Change From Baseline in HADS Depression Total Score at Endpoint
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
All participants were Chinese. 626 participants were randomized initially, as originally stated on clinicaltrials.gov. However, 3 participants discontinued right after randomization without any treatment information. As such, the actual number of participants randomized and assigned to treatment was 623 as stated in the "Started" Row below.
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 314 | 309 |
| Treated | 313 | 307 |
| Completed | 284 | 271 |
| Not completed | 30 | 38 |
| Withdrew: Adverse event | 11 | 9 |
| Withdrew: Other unspecified | 5 | 7 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Insufficient clinical response | 4 | 7 |
| Withdrew: Did not meet entrance criteria | 3 | 4 |
| Withdrew: Randomized but not treated | 1 | 2 |
The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Baseline Mean Pain Score | 6.65 ± 1.117 | 6.67 ± 1.150 |
The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint pain score was obtained from the last 7 available DPRS scores of the daily pain diary while the participant was on study medication, up to and including the day after the last Week 8 (Day 57) dose.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in Mean Pain Score at Endpoint | -2.14 ± 0.115 | -1.86 ± 0.117 |
The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean pain score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 change from baseline (N=312, 307) | -0.60 ± 0.091 | -0.36 ± 0.092 |
| Week 2 change from baseline (N=304, 295) | -0.97 ± 0.092 | -0.71 ± 0.093 |
| Week 3 change from baseline (N=298, 291) | -1.25 ± 0.092 | -1.01 ± 0.093 |
| Week 4 change from baseline (N=297, 289) | -1.47 ± 0.092 | -1.21 ± 0.093 |
| Week 5 change from baseline (N=296, 287) | -1.61 ± 0.092 | -1.39 ± 0.093 |
| Week 6 change from baseline (N=293, 278) | -1.84 ± 0.092 | -1.59 ± 0.094 |
| Week 7 change from baseline (N=290, 275) | -2.04 ± 0.092 | -1.77 ± 0.094 |
| Week 8 change from baseline (N=290, 275) | -2.18 ± 0.092 | -1.88 ± 0.094 |
| Week 9 change from baseline (N=287, 273) | -2.32 ± 0.092 | -2.07 ± 0.094 |
| Overall change from baseline | -1.59 ± 0.082 | -1.33 ± 0.083 |
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Baseline Mean Sleep Interference Score | 5.25 ± 2.236 | 5.12 ± 2.278 |
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint score was obtained from the last 7 available scores of the daily diary while the participant was on study medication, up to and including the day after the last Week 9 (Day 63) dose.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in Mean Sleep Interference Score at Endpoint | -1.52 ± 0.110 | -1.30 ± 0.112 |
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 change from baseline (N=311, 307) | -0.38 ± 0.096 | -0.26 ± 0.098 |
| Week 2 change from baseline (N=303, 295) | -0.66 ± 0.097 | -0.51 ± 0.098 |
| Week 3 change from baseline (N=297, 291) | -0.88 ± 0.097 | -0.72 ± 0.099 |
| Week 4 change from baseline (N=296, 289) | -1.06 ± 0.097 | -0.86 ± 0.099 |
| Week 5 change from baseline (N=295, 287) | -1.14 ± 0.097 | -0.98 ± 0.099 |
| Week 6 change from baseline (N=292, 278) | -1.32 ± 0.098 | -1.07 ± 0.099 |
| Week 7 change from baseline (N=289, 275) | -1.43 ± 0.098 | -1.25 ± 0.099 |
| Week 8 change from baseline (N=289, 275) | -1.59 ± 0.098 | -1.36 ± 0.099 |
| Week 9 change from baseline (N=286, 273) | -1.67 ± 0.098 | -1.49 ± 0.100 |
| Overall change from baseline | -1.13 ± 0.085 | -0.94 ± 0.087 |
The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. A 30% responder was a participant who had 30% reduction or more in mean pain score at the end of the fixed dose phase (Day 63/Week 9) (Study Endpoint) compared to baseline.
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Percentage of 30 Percent (%) Responders at Endpoint | 50.3 ± 0.115 | 44.3 ± 0.117 |
SF-MPQ was assessed according to the participant's answer to the SF-MPQ questionnaire. The score for each composite scale (sensory, affective, and total) was derived by summing the reported intensity value for each item within a particular scale where None=0, Mild=1, Moderate=2, and Severe=3. The sensory score was the sum of the scores of the first 11 pain descriptors (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, and splitting) and could range from 0-33. The affective score was the sum of the scores of the last 4 pain descriptors (tiring-exhausting, sickening, fearful, and punishing-cruel) and could range from 0-12. The total score was the sum of the scores of all 15 pain descriptors and could range from 0 to 45. Higher scores indicated greater pain.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Sensory score, Baseline (N=313, 306) | 7.90 ± 5.101 | 8.11 ± 5.098 |
| Sensory score, Week 1 change (N=311, 304) | -1.50 ± 3.422 | -1.34 ± 3.134 |
| Sensory score, Week 5 change (N=297, 288) | -2.89 ± 4.244 | -2.47 ± 3.925 |
| Sensory score, Week 9 change (N=288, 274) | -3.87 ± 4.432 | -3.37 ± 4.348 |
| Affective score, Baseline (N=313, 307) | 1.25 ± 1.809 | 1.20 ± 1.817 |
| Affective score, Week 1 change (N=311, 304) | -0.41 ± 1.569 | -0.37 ± 1.410 |
| Affective score, Week 5 change (N=297, 289) | -0.72 ± 1.724 | -0.62 ± 1.652 |
| Affective score, Week 9 change (N=287, 274) | -0.75 ± 1.744 | -0.62 ± 1.792 |
| Total score, Baseline (N=313, 307) | 9.15 ± 6.118 | 9.28 ± 6.445 |
| Total score, Week 1 change (N=311, 305) | -1.92 ± 4.260 | -1.70 ± 3.908 |
| Total score, Week 5 change (N=297, 289) | -3.61 ± 5.084 | -3.07 ± 4.893 |
| Total score, Week 9 change (N=288, 274) | -4.62 ± 5.272 | -4.00 ± 5.512 |
The VAS was part of the Short Form McGill Pain Questionnaire (SF-MPQ) scale and reflected the overall pain intensity score, The pain VAS was a horizontal line; 100 millimeters (mm) in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain). The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| VAS | 69.08 ± 11.474 | 69.06 ± 11.811 |
| PPI | 2.28 ± 0.784 | 2.27 ± 0.830 |
The VAS was part of the SF-MPQ scale and reflected the overall pain intensity score. The pain VAS was a horizontal line; 100 mm in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in Pain VAS From the SF-MPQ at Endpoint | -25.07 ± 1.260 | -21.82 ± 1.279 |
The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in PPI Scale From the SF-MPQ at Endpoint | -0.80 ± 0.047 | -0.73 ± 0.048 |
The MOS-Sleep Scale was a participant-rated instrument which assesses sleep quantity and quality with 12 items (7 subscale scores: sleep disturbance, snoring, awakening short of breath/with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep; and a 9-item overall sleep problems index). Subscale scores total range: 0-100 (except sleep quantity \[range 0-24 hours\], optimal sleep \[yes:1, no:0\]). Higher scores=poorer sleep outcomes (except sleep quantity, adequacy, and optimal sleep).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Sleep disturbance score (N=313, 307) | 36.29 ± 24.768 | 35.13 ± 26.915 |
| Snoring score (N=312, 307) | 35.13 ± 36.670 | 37.59 ± 37.163 |
| Awaken short of breath score (N=313, 307) | 11.50 ± 21.557 | 10.75 ± 21.883 |
| Quantity of sleep score (N=311, 304) | 6.07 ± 2.882 | 5.98 ± 1.451 |
| Sleep adequacy score (N=313, 307) | 57.32 ± 31.518 | 60.88 ± 30.274 |
| Somnolence score (N=312, 307) | 33.87 ± 20.459 | 36.03 ± 21.491 |
| Sleep problems index score (N=312, 307) | 32.19 ± 19.806 | 31.21 ± 20.388 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. For sleep disturbance, the subscale score also ranged from 0 to 100, with higher scores representing greater sleep disturbance.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint | -9.11 ± 1.222 | -7.98 ± 1.244 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The snoring subscale score also ranged from 0 to 100, with lower scores indicating less snoring.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint | 2.78 ± 1.716 | -0.53 ± 1.743 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The awaken short of breath subscale also ranged from 0 to 100, with lower scores indicating less difficulty in breathing.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint | -2.10 ± 1.061 | -2.31 ± 1.078 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS Sleep Quantity sub-scale scores ranged from 0 to 24 (number of hours slept).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint | 0.33 ± 0.085 | 0.14 ± 0.087 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS optimal sleep subscale was a binary outcome derived from the sleep quantity responses: the response was YES if sleep quantity was 7 or 8 hours per night.
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Percentage of Participants Who Had Optimal Sleep at Endpoint | 43.8 ± 0.085 | 45.0 ± 0.087 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep adequacy subscale also ranged from 0 to 100, with higher scores indicating greater sleep adequacy.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint | 8.87 ± 1.532 | 7.82 ± 1.552 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The somnolence subscale score also ranged from 0 to 100, with lower scores indicating less somnolence.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint | -1.22 ± 1.187 | -0.88 ± 1.208 |
The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep problems index subscale score also ranged from 0 to 100, with lower scores indicating fewer sleep problems.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint | -6.71 ± 0.914 | -5.88 ± 0.927 |
The CGIC was a clinician-rated global measure that provided a clinically relevant and easy to interpret account of a clinician's perception of the clinical importance of the participant's improvement or worsening during their involvement in a clinical study. Clinicians rated the participant's overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGIC) at Endpoint | 2.58 ± 0.057 | 2.73 ± 0.058 |
The PGIC was a participant-rated global measure that provided a clinically relevant and easy to interpret account of a participant's perception of the clinical importance of their own improvement or worsening during their involvement in a clinical study. Participants rated their overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Patient Global Impression of Change (PGIC) Score at Endpoint | 2.60 ± 0.057 | 2.74 ± 0.058 |
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Anxiety total score | 3.76 ± 3.800 | 3.67 ± 3.645 |
| Depression total score | 4.45 ± 4.081 | 4.35 ± 3.798 |
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in HADS Anxiety Total Score at Endpoint | -0.48 ± 0.161 | -0.31 ± 0.163 |
The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.
| units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline in HADS Depression Total Score at Endpoint | -0.57 ± 0.169 | -0.38 ± 0.172 |
Collected over From Baseline till Week 10 (Day 70) and/or Early Termination.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 7/314 (2.2%) | 77/314 (24.5%) |
| Placebo | — | 5/308 (1.6%) | 55/308 (17.9%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| Cerebral infarctionNervous system disorders | 1/314 | 2/308 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/314 | 1/308 |
| InfectionInfections and infestations | 0/314 | 1/308 |
| GliomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/314 | 1/308 |
| Hypoglycaemic comaNervous system disorders | 0/314 | 1/308 |
| Cardiac failureCardiac disorders | 1/314 | 0/308 |
| CataractEye disorders | 1/314 | 0/308 |
| GastroenteritisInfections and infestations | 1/314 | 0/308 |
| Basal ganglia haemorrhageNervous system disorders | 1/314 | 0/308 |
| Diabetic neuropathyNervous system disorders | 1/314 | 0/308 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 30/314 | 12/308 |
| SomnolenceNervous system disorders | 18/314 | 6/308 |
| Urinary tract infectionInfections and infestations | 7/314 | 12/308 |
| Oedema peripheralGeneral disorders | 10/314 | 1/308 |
| DiarrhoeaGastrointestinal disorders | 6/314 | 7/308 |
| Upper respiratory tract infectionInfections and infestations | 7/314 | 6/308 |
| NasopharyngitisInfections and infestations | 4/314 | 6/308 |
| HeadacheNervous system disorders | 4/314 | 6/308 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/314 | 5/308 |
| NauseaGastrointestinal disorders | 5/314 | 0/308 |
The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.
| Age, Customized(participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| 18-44 years | 25 ± 10.3 | 15 ± 9.5 | 40 |
| 45-64 years | 172 | 178 | 350 |
| More than or equal to (>=) 65 years | 116 | 114 | 230 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 159 | 168 | 327 |
| Male | 154 | 139 | 293 |
The record gives a start of Jul 2011, a primary completion of Apr 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →